By April 2015, the Ebola virus had already spread through West Africa. But case numbers had started falling, so there were fewer areas of high infection available for real-world trials. And that meant scientists could only test one vaccine at a time.
This is the key message: Work on the Ebola vaccine paved the way for enhanced vaccine technology.
Working with the labs, public health organizations began testing one Ebola vaccine, known as VSV, in one region. The plan was then to switch to the second one in development, called the ChAd3 EBOZ vaccine, later on. By June 2016, with the help of contact tracing, quarantine, and the VSV vaccine, the outbreak had been contained. The ChAd3 vaccine was no longer needed, and there was no demand for continuing clinical trials.
When the WHO – the World Health Organization – put out a list of high-priority diseases in 2016, it included SARS, MERS, and Ebola, aiming to better prepare for the next big outbreak. It was a perfect opportunity for one of the coauthors, Sarah, and her lab at the University of Oxford to ramp up work on similar vaccine technology called ChAdOx1, which they’d been working on parallel to the scrapped Ebola project.
Like the ChAd3 Ebola vaccine, ChAdOx1 is based on an adenovirus, a type of virus that causes cold symptoms like runny noses and sore throats in humans. Most humans already have antibodies against common adenoviruses. That’s why those from chimpanzees – known as simian adenoviruses – generate stronger immune responses in humans.
The Oxford scientists took the adenovirus and removed the gene that enables it to make copies of itself and spread throughout a host’s body. As a result, it became replication-deficient. The gene was then replaced – or recombined – with a different gene that tells infected cells to produce the virus’s protein. This triggers an immune response that creates antibodies to suppress the virus before the recipient ever actually comes into contact with it; in other words, the body learns to fight the virus without ever getting sick. And there Sarah and her team had it – the basis for a replication-deficient recombinant simian adenoviral-vectored vaccine.
By refining this method, they were able to create a new type of platform technology, which is a predesigned framework upon which vaccines can be built. This would allow them to create vaccines for other diseases quickly, including ones that didn’t yet exist.